Compare Viatris Inc (VTRS) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Vanguard Ultra Short Bond ETF trades at $49.71. The key difference: Viatris Inc pays a 2.83% dividend while Vanguard Ultra Short Bond ETF pays none, and Viatris Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| VTRS | VUSB | |
|---|---|---|
Market Cap | $19.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $17.39 | $50.03 |
52-Week Low | $8.74 | $49.60 |
Enterprise Value | $32.00B | — |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
VUSB trades at $49.70, showing minimal daily movement with a slight 0.02% gain. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Recent dividend payments of $0.17-$0.18 per share indicate ongoing shareholder returns. Financial media highlights potential benefits from Federal Reserve policy shifts favoring short-term bonds.
The outlook remains cautiously optimistic given the ETF's focus on short-term bonds amid potential rate hikes. Key risks include interest rate sensitivity and market volatility. Analyst sentiment appears balanced, with technical indicators suggesting near-term consolidation around current price levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
